DEFAR - Departamento de Farmácia

Permanent URI for this community

https://monog.ufop.br/handle/123456789/530

Browse

Browsing DEFAR - Departamento de Farmácia by Subject "Acute myocardial infarction"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion.
    (2022) Amancio, Gabriela de Cássia Sousa; Hermidorff, Milla Marques; Alvarenga, Ana Cláudia; Lima, Wanderson Geraldo de; Guimarães, Homero Nogueira; Rodrigues, Henrique Resende; Silva, Emília Calil; Assis, Leonardo Vinícius Monteiro de; Guimarães, Andrea Grabe; Isoldi, Mauro César
    Introduction: Mineralocorticoid receptor antagonists (MRAs) are effective in reducing left ventricle remodeling and sudden death after acute myocardial infarction (AMI). Objectives: MRAs in vitro display cardioprotective effects, independent of MR; however, it is unknown whether the rapid effects of MRAs are cardioprotective in vivo. This study evaluated the acute effects of spironolactone and eplerenone in the first minutes of AMI. Methods: Wistar Rats, submitted or not to bilateral adrenalectomy, were treated orally with spironolactone (20 mg/kg) or eplerenone (10 mg/kg), and submitted to the left coronary ligation, under anesthesia. Electrocardiogram (ECG) recordings were obtained to evaluate ST-T segment, QT, and QTc intervals. Arterial pressure was also measured before (baseline) and after coronary ligation. Results: Spironolactone or eplerenone given, one hour before coronary ligation, prevented ST- T segment elevation in adrenalectomized and non-adrenalectomized. QT interval analysis showed that MRAs prevented its prolongation after coronary ligation. QT and QTc intervals remained similar to baseline and were smaller than the values displayed by the non-treated group. Animals treated with spironolactone, regardless of adrenalectomy, showed a 3-fold reduced mortality rates compared to the control group. Conclusion: MRAs display acute cardioprotective effects in early phase of AMI, which are independent of aldosterone.